Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 104912, 8 pages
http://dx.doi.org/10.1155/2015/104912
Review Article

Targeting of Prosurvival Pathways as Therapeutic Approaches against Primary Effusion Lymphomas: Past, Present, and Future

Department of Experimental Medicine, Istituto Pasteur Fondazione Cenci Bolognetti, Sapienza University, 00161 Rome, Italy

Received 28 February 2014; Accepted 29 October 2014

Academic Editor: Panayiotis Panayiotidis

Copyright © 2015 Marisa Granato et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Boshoff and R. Weiss, “AIDS-related malignancies,” Nature Reviews Cancer, vol. 2, no. 5, pp. 373–382, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. R. G. Nador, E. Cesarman, A. Chadburn et al., “Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus,” Blood, vol. 88, no. 2, pp. 645–656, 1996. View at Google Scholar · View at Scopus
  3. E. Cesarman, R. G. Nador, K. Aozasa, G. Delsol, J. W. Said, and D. M. Knowles, “Kaposi's sarcoma-associated herpesvirus in non-AIDS-related lymphomas occurring in body cavities,” The American Journal of Pathology, vol. 149, no. 1, pp. 53–57, 1996. View at Google Scholar · View at Scopus
  4. W. Fan, D. Bubman, A. Chadburn, W. J. Harrington Jr., E. Cesarman, and D. M. Knowles, “Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association,” Journal of Virology, vol. 79, no. 2, pp. 1244–1251, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Ensoli and A. Cafaro, “Novel strategies toward the development of an effective vaccine to prevent human immunodeficiency virus infection or acquired immunodeficiency virus,” AIDS Clinical Review, vol. 18, no. 4, pp. 23–61, 2000. View at Google Scholar · View at Scopus
  6. H. G. Drexler, C. Meyer, G. Gaidano, and A. Carbone, “Constitutive cytokine production by primary effusion (body cavity-based) lymphoma-derived cell lines,” Leukemia, vol. 13, no. 4, pp. 634–640, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Haddad, H. El Hajj, R. Abou-Merhi et al., “KSHV-transformed primary effusion lymphoma cells induce a VEGF-dependent angiogenesis and establish functional gap junctions with endothelial cells,” Leukemia, vol. 22, no. 4, pp. 826–834, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. K. D. Jones, Y. Aoki, Y. Chang, P. S. Moore, R. Yarchoan, and G. Tosato, “Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells,” Blood, vol. 94, no. 8, pp. 2871–2879, 1999. View at Google Scholar · View at Scopus
  9. J. Osborne, P. S. Moore, and Y. Chang, “KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways,” Human Immunology, vol. 60, no. 10, pp. 921–927, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Yamin, N. S. Kaynan, A. Glasner et al., “The viral KSHV chemokine vMIP-II inhibits the migration of naive and activated human NK cells by antagonizing two distinct chemokine receptors,” PLoS Pathogens, vol. 9, no. 8, Article ID e1003568, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Niu, K. L. Wright, M. Huang et al., “Constitutive stat3 activity up-regulates VEGF expression and tumor angiogenesis,” Oncogene, vol. 21, no. 13, pp. 2000–2008, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. D. A. Braun, M. Fribourg, and S. C. Sealfon, “Cytokine response is determined by duration of receptor and signal transducers and activators of transcription 3 (STAT3) activation,” The Journal of Biological Chemistry, vol. 288, no. 5, pp. 2986–2993, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Uddin, A. R. Hussain, P. S. Manogaran et al., “Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma,” Oncogene, vol. 24, no. 47, pp. 7022–7030, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Aoki, G. M. Feldman, and G. Tosato, “Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma,” Blood, vol. 101, no. 4, pp. 1535–1542, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Cirone, L. Di Renzo, L. V. Lotti et al., “Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91,” PLoS ONE, vol. 7, no. 3, Article ID e31732, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Garufi, G. Pistritto, C. Ceci et al., “Targeting COX-2/PGE2 pathway in HIPK2 knockdown cancer cells: impact on dendritic cell maturation,” PLoS ONE, vol. 7, no. 11, Article ID e48342, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Ma, R. Conforti, L. Aymeric et al., “How to improve the immunogenicity of chemotherapy and radiotherapy,” Cancer and Metastasis Reviews, vol. 30, no. 1, pp. 71–82, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. T. S. Griffith and T. A. Ferguson, “Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cells,” Immunity, vol. 35, no. 4, pp. 456–466, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. U. Bharadwaj, M. Li, R. Zhang, C. Chen, and Q. Yao, “Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation,” Cancer Research, vol. 67, no. 11, pp. 5479–5488, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Xu, Y. Zhang, Y. Hua, T. Chen, H. Wang, and W. Wu, “IL-12 p35 silenced dendritic cells modulate immune responses by blocking IL-12 signaling through JAK-STAT pathway in T lymphocytes,” Biochemical and Biophysical Research Communications, vol. 353, no. 3, pp. 812–816, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. S. L. Fossey, M. D. Bear, W. C. Kisseberth, M. Pennell, and C. A. London, “Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines,” BMC Cancer, vol. 11, article 125, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Arita, A. P. South, G. Hans-Filho et al., “Oncostatin M receptor-β mutations underlie familial primary localized cutaneous amyloidosis,” The American Journal of Human Genetics, vol. 82, no. 1, pp. 73–80, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. A. P. Bhatt and B. Damania, “AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV,” Frontiers in Immunology, vol. 3, Article ID Article 401, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. C. C. Tomlinson and B. Damania, “The K1 protein of Kaposi's Sarcoma-Associated Herpesvirus activates the AKT signaling pathway,” Journal of Virology, vol. 78, no. 4, pp. 1918–1927, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Uddin, A. R. Hussain, K. A. Al-Hussein et al., “Inhibition of phosphatidylinositol 3′-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells,” Clinical Cancer Research, vol. 11, no. 8, pp. 3102–3108, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. A. P. Bhatt, P. M. Bhende, S.-H. Sin, D. Roy, D. P. Dittmer, and B. Damania, “Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas,” Blood, vol. 115, no. 22, pp. 4455–4463, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Gonnella, R. Santarelli, A. Farina et al., “Kaposi sarcoma associated herpesvirus (KSHV) induces AKT hyperphosphorylation, bortezomib-resistance and GLUT-1 plasma membrane exposure in THP-1 monocytic cell line,” Journal of Experimental and Clinical Cancer Research, vol. 32, no. 1, article 79, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. S.-H. Sin, D. Roy, L. Wang et al., “Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling,” Blood, vol. 109, no. 5, pp. 2165–2173, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. G. L. Johnson and R. Lapadat, “Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases,” Science, vol. 298, no. 5600, pp. 1911–1912, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Dai, R. Chen, and H. Li, “Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells,” International Journal of Oncology, vol. 34, no. 6, pp. 1749–1757, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Granato, R. Santarelli, L. V. Lotti et al., “JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells,” PLoS ONE, vol. 8, no. 9, Article ID e75965, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Raciti, L. V. Lotti, S. Valia, F. M. Pulcinelli, and L. Di Renzo, “JNK2 is activated during ER stress and promotes cell survival,” Cell Death and Disease, vol. 3, no. 11, article e429, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. S. A. Keller, E. J. Schattner, and E. Cesarman, “Inhibition of NF-κB induces apoptosis of KSHV-infected primary effusion lymphoma cells,” Blood, vol. 96, no. 7, pp. 2537–2542, 2000. View at Google Scholar · View at Scopus
  34. R. Gopalakrishnan, H. Matta, and P. M. Chaudhary, “A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP k13-induced NF-κB,” Clinical Cancer Research, vol. 19, no. 18, pp. 5016–5026, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Matta and P. M. Chaudhary, “The proteasome inhibitor Bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells,” Cancer Biology and Therapy, vol. 4, no. 1, pp. 77–82, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. P. G. Richardson, C. Mitsiades, T. Hideshima, and K. C. Anderson, “Bortezomib: proteasome inhibition as an effective anticancer therapy,” Annual Review of Medicine, vol. 57, pp. 33–47, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Cirone, L. Di Renzo, L. V. Lotti et al., “Activation of dendritic cells by tumor cell death,” OncoImmunology, vol. 1, no. 7, pp. 1218–1219, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Chatterjee, S. Jain, T. Stühmer et al., “STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90α and β in multiple myeloma cells, which critically contribute to tumor-cell survival,” Blood, vol. 109, no. 2, pp. 720–728, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Chatterjee, M. Andrulis, T. Stühmer et al., “The PI3k/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma,” Haematologica, vol. 98, no. 7, pp. 1132–1141, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Granato, V. Lacconi, M. Peddis et al., “HSP70 inhibition by 2-phenylethynesulfonamide induces lysosomal cathepsin D release and immunogenic cell death in primary effusion lymphoma,” Cell Death and Disease, vol. 4, no. 7, article e730, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Higashi, C. Saji, K. Yamada et al., “The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells,” Biological and Pharmaceutical Bulletin, vol. 35, no. 5, pp. 725–730, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. U. Nayar, P. Lu, R. L. Goldstein et al., “Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies,” Blood, vol. 122, no. 16, pp. 2837–2847, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Lamottke, M. Kaiser, M. Mieth et al., “The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases,” European Journal of Haematology, vol. 88, no. 5, pp. 406–415, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. R. G. Jenner, K. Maillard, N. Cattini et al., “Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 18, pp. 10399–10404, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. H.-J. Wen, Z. Yang, Y. Zhou, and C. Wood, “Enhancement of autophagy during lytic replication by the Kaposi's sarcoma-associated herpesvirus replication and transcription activator,” Journal of Virology, vol. 84, no. 15, pp. 7448–7458, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. N. Kanarek and Y. Ben-Neriah, “Regulation of NF-κB by ubiquitination and degradation of the IκBs,” Immunological Reviews, vol. 246, no. 1, pp. 77–94, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. R. Santarelli, R. Gonnella, G. Di Giovenale et al., “STAT3 activation by KSHV correlates with IL-10, IL-6 and IL-23 release and an autophagic block in dendritic cells,” Scientific Reports, vol. 4, article 4241, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Wakao, T. Watanabe, T. Takadama et al., “Sangivamycin induces apoptosis by suppressing Erk signaling in primary effusion lymphoma cells,” Biochemical and Biophysical Research Communications, vol. 444, no. 2, pp. 135–140, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. K. W. Wen and B. Damania, “Hsp90 and Hsp40/Erdj3 are required for the expression and anti-apoptotic function of KSHV K1,” Oncogene, vol. 29, no. 24, pp. 3532–3544, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. W. Chen, S.-H. Sin, K. W. Wen, B. Damania, and D. P. Dittmer, “Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins,” PLoS Pathogens, vol. 8, no. 11, Article ID e1003048, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Soldani and A. I. Scovassi, “Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update,” Apoptosis, vol. 7, no. 4, pp. 321–328, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Banchereau, F. Briere, C. Caux et al., “Immunobiology of dendritic cells,” Annual Review of Immunology, vol. 18, pp. 767–811, 2000. View at Publisher · View at Google Scholar · View at Scopus